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Kasabach-Merritt Syndrome (KMS) is an uncommon phenomenon characterized by the presence of a
vascular tumor in association with thrombocytopenia, consumption coagulopathy and hemodynamic
instability. Typically presents in infancy and involve the skin and deep soft tissues of the arms and legs.
Treatment options vary with clinical presentation, and ranges from medical management to immediate
surgical intervention. We present an unusual case of a newborn with KMS and fatal hemodynamic
collapse imminent, which was successfully treated with surgical resection at our institution.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Kasabach-Merritt Syndrome (KMS) is a rare and potentially life
threatening phenomenon characterized by profound thrombocy-
topenia and consumption coagulopathy in the presence of a rapidly
enlarging vascular tumor [1,2]. We report a case of a newborn male
who presented with KMS resulting from a massive upper extremity
vascular tumor.1. Case
A 3.l kgmalewas bornwith an extensive upper extremity tumor.
His prenatal evaluation included ultrasonography and an MRI
(Fig. 1), which both revealed the mass was consistent with a
vascular tumor. Moderate cardiomegaly and decreased biven-
tricular function were also documented. Given the size of the mass,
elective caesarian section was planned at term, but due to
decreased fetal movement along with nonreactive Non-Stress test
(NST), an urgent C-section was performed at thirty-seven weeks
gestation. The baby was bornwith an APGAR score of 1, 1 at one and
5 min respectively. He was immediately noted to be severely bra-
dycardic, hypotensive and in profound respiratory distress.
Maximum cardio pulmonary resuscitationwas undertakenwithout
delay.
During the resuscitation period, the surgical team quickly
recognized that the vascular tumor was enlarging at a precipitousn).
Inc. This is an open access article urate, extending from the mid-upper right arm to the wrist, and was
noted to measure 11  11  8 cm. Further examination of the limb
showed signiﬁcant ecchymosis and a pale, pulseless hand with no
spontaneous movement. The mass was thought to be causing high
output cardiac failure with resulting hemodynamic instability.
Signiﬁcant bleeding within the tumor with sequestration was also
noted. Initial laboratory evaluation provided evidence of severe
metabolic acidosis with a pH of 6.87, anemia (Hb 5.8 g/dL),
thrombocytopenia (41,000 mm3), and low ﬁbrinogen (52 mg/dL).
The neonate remained hypotensive despite multi-agent volume
expansion and the administration of full pharmacologic hemody-
namic support.
With the clinical presentation of hemodynamic instability,
consumption coagulopathy, thrombocytopenia, and a presumptive
diagnosis of KMS with fatal hemodynamic collapse imminent, it
was decided to place a tourniquet proximal to the tumor (Fig. 2).
This resulted in a marked hemodynamic improvement, and
following the completion of essential resuscitative measures the
baby was transferred to the operating room.
The procedure was initiated with dissection at the level of the
superior aspect of the mass, by identifying and isolating the axillary
artery and vein with vessel loops. After proximal vascular control
was adequately achieved, we proceeded to remove the previously
placed tourniquet. The dissection was then continued along the
posterior and lateral aspect of the tumor where several large
feeding arteries and draining veins were ligated (Figs. 3 and 4). The
median and ulnar nerves were located and preserved. A surgical
plane of dissection was established antero-medially, whichnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Fetal MRI showing the vascular tumor.
Fig. 3. Initiation of the dissection.
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vascular control was then released conﬁrming improved perfusion
and a viable hand (Fig. 5). Owing to the extensive dissection
required to remove the tumor, the defect in the baby’s arm was
sizeable. For this reason, the wound was left open and wrapped
with sterile gauze.Fig. 2. Preoperative image showing large massThe baby’s post-operative course was largely uneventful with
marked hemodynamic and metabolic improvement. Daily
improvement in the perfusion of his hand was also noted. Plastic
Surgical consultation was obtained to assist with deﬁnitive wound
closure. On post-operative day four, debridement of the wound and
negative pressure wound therapy were initiated (Wound V.A.C.
system). One week following the procedure, the patient was noted
to have ﬂexion and extension of his ﬁngers. Split thickness skin
grafting was successfully carried out, and at two months of age, he
was discharged. At one year of age, he continues to develop nor-
mally and has full range of motion of the right arm and hand (Fig. 6).with tourniquet (Penrose drain) in place.
Fig. 4. Mass at near completion of removal. Note the large venous channels.
Fig. 6. Arm at 1 year follow up.
M. Sasson et al. / J Ped Surg Case Reports 3 (2015) 462e465464Final pathologic analysis classiﬁed the extensive mass as
a congenital benign vascular tumor without the classic
features of either a congenital hemangiomas or a Kaposiform
hemangioendothelioma.
2. Discussion
The infant we present was born with a large vascular tumor
of his right upper arm in association with a consumption coa-
gulopathy and thrombocytopenia. These ﬁndings are pathogno-
monic for Kasabach-Merritt Syndrome [1e3]. KMS is a
potentially life threatening phenomenon seen in association
with large vascular tumors [1,2]. First described in 1940 [4], itFig. 5. Appearance of arm following complete removal of the vascular tumor.remains a rare condition with less than 300 cases described in
the literature [5]. The most common vascular tumor associated
with KMS are kaposiform hemangioendothelioma (KHE) and
tufted angioma. Approximately 70 percent of patients with KHE
and 10 percent of those with tufted angiomas will develop this
phenomenon [1,6].
Vascular tumors associated with KMS may be present at birth
or develop in early infancy and childhood. These neoplasms
typically involve skin and deep soft tissues of the arms and legs.
The trunk, retroperitoneum and thoracic cavity are less commonly
affected [6,7]. Superﬁcial lesions will often show a well-circum-
scribed mass with purpura, while severe KMS will present with
vascular limb tumors that are painful and rapidly enlarging. They
are frequently indurated with a red-purple hue and may involve
all or a signiﬁcant portion of the affected extremity. These cases
are frequently associated with thrombocytopenia, severe anemia,
hypoﬁbrinogenemia and elevated ﬁbrin degradation products
[8,9]. Mortality rates from KMS have been reported to be as high as
10e37% [6,10]. The most important factors that negatively affect
survival are the location of the tumor, its size and delay in
diagnosis.
In 2011, a multi-disciplinary expert panel developed a
consensus-derived treatment protocol that resulted in a compre-
hensive guideline for the management of complicated KHE [2]. The
committee strongly recommended amulti-disciplinary approach to
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embolization, and in patients who are hemodynamically unstable
or those with threatened limb loss, urgent surgical intervention
[1,2,11].
Although complete surgical resection has been considered the
gold standard in the treatment of KHE, this option is oftentimes
associated with an unacceptably high morbidity and mortality and
can preclude total excision. However, for patients with life
threatening tumors and for those who have failed non-operative
management, surgical resection becomes the only viable option
[3,12,13].
The medical management of KMS is aimed at decreasing the
size of the tumor and correction of the coagulopathy. Speciﬁc
therapeutic modalities widely utilized for KMS include systemic
corticosteroids, antiplatelet agents, vincristine and interferon-a
[2,14]. More recently, the mTOR inhibitor sirolimus has been
used for KHE with KMS [15,16], and a Phase II clinical trial is
underway to evaluate the safety and efﬁcacy of the medication
in complicated vascular anomalies (ClinicalTrials.gov
NCT00975819).
However, pharmacologic therapy oftentimes requires weeks to
months to be effective rendering this option unacceptable for the
patient with a worsening consumption coagulopathy and hemo-
dynamic instability [2,17,18]. The infant we report is unique because
he was profoundly symptomatic at birth. Although, benign vascular
tumors may be present at birth, KMS is rare. More typically, the
syndrome presents in infancy but after the ﬁrst month of life [19]. It
is also noteworthy that infants who are diagnosed prenatally or in
the immediate neonatal period characteristically develop a more
advanced disease severity [2].
In conclusion, this case lends credence to the concept that a
multi-disciplinary approach coupled with prompt surgical inter-
vention are key elements in achieving a favorable outcome in in-
fants stricken with KMS. The immediate postnatal resuscitative
measures coupled with rapid surgical intervention and subsequent
collaboration with our Division of Plastic Surgery were directly
responsible for both salvaging the baby’s arm in the proximate
neonatal period and the subsequent excellent outcome from both a
functional and cosmetic standpoint.Conﬂicts of interest
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